Release details

2016-01-18 08:35 CET
  • Print
  • Share Share
en de

aap: Sales in Q4/2015 at EUR 6.7 million and in FY/2015 at EUR 28.7 million

aap Implantate AG (XETRA: AAQ.DE) generated sales of EUR 6.7 million (Q4/2014: EUR 8.6 million) in the fourth quarter of 2015 according to preliminary figures. Sales in the full financial year 2015 totalled EUR 28.7 million (FY/2014: EUR 30.6 million) and were thus within the guidance of EUR 27.5 million to EUR 31.5 million announced in November 2015.

In EUR million
Q4/2015 Q4/2014 Change
Sales 6.7 8.6 -22%
Trauma 2.7 3.9 -31%
thereof LOQTEQ® 1.6 2.9 -45%
Biomaterials 3.7 3.7 0%
Projects 0.1 0.9 -90%
Other 0.2 0.1 >100%

 In EUR million
FY/2015 FY/2014 Change
Sales 28.7 30.6 -6%
Trauma 11.0 12.2 -10%
thereof LOQTEQ® 6.8 8.2 -17%
Biomaterials 16.8 16.4 2%
Projects 0.3 1.2 -76%
Other 0.6 0.8 -20%
In the trauma business, aap Implantate AG realized sales of EUR 2.7 million (Q4/2014: EUR 3.9 million) in the fourth quarter of 2015. In the full year 2015 sales in the trauma business totalled EUR 11.0 million (FY/2014: EUR 12.2 million). The background to the decline in year-on-year trauma sales is, especially, the deteriorated economic framework conditions in several markets in the BRICS and SMIT states, which have been focal points of the company's growth strategy so far, and led to deviations from the sales development originally anticipated. At the same time the planned sales contribution from the US market has not yet materialised due to protracted administrative processes in hospitals.
The Management Board is confident the company will return to its growth path in the current financial year by means of the measures initiated, which are aimed primarily at intensifying sales activities in relatively more stable markets in Europe.  In addition, the US market is to become a mainstay of aap Implantate AG's growth strategy in 2016.
In the biomaterials business, aap Implantate AG generated sales of EUR 3.7 million in the fourth quarter of 2015 which were at the same level as in the previous year (Q4/2014: EUR 3.7 million). Overall, the biomaterials business registered again a satisfactory sales development in financial year 2015, with sales up slightly on the previous year to EUR 16.8 million (FY/2014: EUR 16.4 million). As part of the strategy to transform aap Implantate AG into a focussed trauma company the necessary steps for a divestment of aap Biomaterials GmbH have been initiated already in the previous financial year. The company has put in place a structured process to take this forward and will be reporting on its progress.
In the silver coating technology area, approval-relevant work went ahead on schedule in the fourth quarter of 2015. On the basis of the current state of development and subject to the results of current consultations with the approval authorities aap Implantate AG plans to submit the CE approval application for the silver coating technology by the end of January 2016.
The results contained in this press release are preliminary figures based on an initial analysis by the Management Board for the period ended on 31 December 2015 and are therefore subject to change. aap Implantate AG plans to publish the final, audited results for the financial year 2015 on 30 March 2016.
In a further press release at the beginning of February 2016 the company will provide information about the outlook for the first quarter of 2016 and the full financial year 2016.

About aap Implantate AG

aap Implantate AG is a globally operating medical device company headquartered in Berlin, Germany. The company develops, manufactures and markets trauma and biomaterials products for orthopedics. The trauma portfolio includes besides the innovative anatomical plating system LOQTEQ® a wide range of cannulated screws as well as standard plates and screws. In the biomaterials business the company is specialized on bone cements and mixing systems. In German-speaking countries aap Implantate AG directly sells its trauma products to hospitals, buying syndicates and hospital groups while it uses a broad network of distributors in more than 60 countries at the international level. In the biomaterials business sales are handled via OEM and private label cooperations with several selected international orthopedic and trauma companies. aap Implantate AG's stock is listed in the Prime Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit, or download the Company's investor relations app from the Apple's App Store or Google Play.

Forward-looking statement

This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.

For inquiries please contact: aap Implantate AG, Fabian Franke, Investor Relations, Lorenzweg 5, 12099 Berlin, Germany

Tel.: +49 30 7501 9-134, fax: +49 30 7501 9-290, e-mail: